Prohibitin-2 Mitochondrial Cross-Seeding Hub Disruption
Target: PHB2
Composite Score: 0.469
Price: $0.47▲74.3%
Citation Quality: Pending
neurodegeneration
Status: proposed
🟢 Parkinson's Disease 🔮 Lysosomal / Autophagy 🔥 Neuroinflammation 🔴 Alzheimer's Disease 🟡 ALS / Motor Neuron Disease 🧠 Neurodegeneration
✓ All Quality Gates Passed
Quality Report Card click to collapse
C
Composite: 0.469
Top 81% of 1302 hypotheses
T1 Established
Multi-source converged and validated
T0 Axiom requires manual override only
C+
0.55
Top 69%
C
0.45
Top 76%
B+
0.75
Top 36%
D
0.30
Top 91%
C+
0.50
Top 82%
D
0.25
Top 94%
D
0.30
Top 92%
A
0.80
Top 22%
C
0.40
Top 87%
D
0.35
Top 92%
Evidence
3 supporting
|
3 opposing
Citation quality: 100%
Debates
1 session
A+
Avg quality: 0.95
Convergence
1.00
A+
30 related hypothesis share this target
From Analysis:
Protein aggregation cross-seeding across neurodegenerative diseases
What are the mechanisms underlying protein aggregation cross-seeding across neurodegenerative diseases?
Hypotheses from Same Analysis (6)
These hypotheses emerged from the same multi-agent debate that produced this hypothesis.
Transglutaminase-2 Cross-Linking Inhibition Strategy
Score: 0.639 | Target: TGM2
Glycosaminoglycan Template Disruption Approach
Score: 0.597 | Target: HSPG2
TREM2-Mediated Selective Aggregate Clearance Pathway
Score: 0.584 | Target: TREM2
Liquid-Liquid Phase Separation Modifier Therapy
Score: 0.551 | Target: G3BP1
HSP70 Co-chaperone DNAJB6 Universal Cross-Seeding Inhibitor
Score: 0.544 | Target: DNAJB6
RNA-Binding Competition Therapy for TDP-43 Cross-Seeding
Score: 0.465 | Target: TARDBP
Description
Prohibitin-2 serves as a convergent mitochondrial platform where tau, α-synuclein, and TDP-43 interact and undergo conformational templating. Selective prohibitin-2 modulators could disrupt this cross-seeding hub while preserving essential mitochondrial functions through compartment-specific targeting.
No AI visual card yet
Curated Mechanism Pathway
Curated pathway diagram from expert analysis
graph TD
A["PHB2 on Mitochondrial Inner Membrane"] --> B["Scaffolding/Structural Role"]
B --> C["Cristae Organization"]
B --> D["Mitophagy Receptor Function"]
E["Tau"] --> F["Binds PHB2 on Mito Surface"]
G["alpha-Synuclein"] --> F
H["TDP-43"] --> F
F --> I["PHB2 as Convergent Cross-Seeding Hub"]
I --> J["Conformational Templating"]
J --> K["Heterologous Protein Aggregation"]
K --> L["Multi-Protein Toxic Complexes"]
L --> M["Mitochondrial Membrane Disruption"]
M --> N["Bioenergetic Collapse"]
N --> O["Neurodegeneration"]
P["PHB2 Modulator Therapy"] --> Q["Disrupt PHB2-Aggregate Interaction"]
Q --> R["Block Cross-Seeding Platform"]
R --> S["Prevent Multi-Protein Aggregation"]
Q --> T["Preserve PHB2 Scaffolding Function"]
T --> U["Maintained Cristae Integrity"]
S --> V["Neuroprotection"]
U --> V
style A fill:#264653,stroke:#ffd54f,color:#e0e0e0
style I fill:#3a1a1a,stroke:#ef9a9a,color:#e0e0e0
style P fill:#1a3a4a,stroke:#4fc3f7,color:#e0e0e0
style V fill:#2a3a1a,stroke:#c5e1a5,color:#e0e0e0
3D Protein Structure (AlphaFold)
Open full viewerAlphaFold predicted structure available for Q99623
View AlphaFold StructureDimension Scores
How to read this chart:
Each hypothesis is scored across 10 dimensions that determine scientific merit and therapeutic potential.
The blue labels show high-weight dimensions (mechanistic plausibility, evidence strength),
green shows moderate-weight factors (safety, competition), and
yellow shows supporting dimensions (data availability, reproducibility).
Percentage weights indicate relative importance in the composite score.
6 citations
6 with PMID
Validation: 100%
3 supporting / 3 opposing
✓
For
(3)
(3)
Against
✗
High
Medium
Low
High
Medium
Low
Evidence Matrix
— sortable by strength/year, click Abstract to expand
Evidence Types
MECH 6CLIN 0GENE 0EPID 0
Legacy Card View — expandable citation cards
✓ Supporting Evidence 3
Prohibitin-2 interacts directly with both tau and α-synuclein at mitochondria
TDP-43 pathology involves mitochondrial dysfunction and prohibitin complex disruption
Prohibitin-2 modulates protein aggregation through conformational changes
✗ Opposing Evidence 3
Prohibitin-2 is essential for mitochondrial function, making selective modulation challenging
TDP-43 mitochondrial localization may be secondary to other pathological processes
Prohibitin complex disruption often reflects rather than causes neurodegeneration
Multi-persona evaluation:
This hypothesis was debated by AI agents with complementary expertise.
The Theorist explores mechanisms,
the Skeptic challenges assumptions,
the Domain Expert assesses real-world feasibility, and
the Synthesizer produces final scores.
Expand each card to see their arguments.
Gap Analysis | 4 rounds | 2026-04-01 | View Analysis
🧬 Theorist Proposes novel mechanisms and generates creative hypotheses ▼
Novel Therapeutic Hypotheses for Cross-Seeding in Neurodegeneration
Hypothesis 1: HSP70 Co-chaperone DNAJB6 Universal Cross-Seeding Inhibitor
Description: DNAJB6 specifically recognizes and suppresses amyloidogenic β-sheet conformations shared across tau, α-synuclein, and TDP-43 aggregates. Enhanced DNAJB6 expression or small molecule activators could provide broad-spectrum protection against cross-seeding by disrupting the common structural motifs that enable heterologous nucleation.Target: DNAJB6 (DnaJ heat shock protein family member B6)
Supporting Evidence: DNAJB6 pote
🔍 Skeptic Identifies weaknesses, alternative explanations, and methodological concerns ▼
I'll critically evaluate each hypothesis, identifying weaknesses and providing counter-evidence where available.
Hypothesis 1: DNAJB6 Universal Cross-Seeding Inhibitor
Specific Weaknesses:
- The evidence primarily focuses on polyglutamine aggregation, not tau, α-synuclein, or TDP-43
- No direct evidence that DNAJB6 inhibits cross-seeding between different protein types
- The cited PMIDs don't actually support cross-seeding inhibition claims
- DNAJB6 overexpression can actually promote tau aggregation in some contexts by interfering with normal proteostasis (PMID
🎯 Domain Expert Assesses practical feasibility, druggability, and clinical translation ▼
PRACTICAL FEASIBILITY ASSESSMENT
Hypothesis 1: DNAJB6 Universal Cross-Seeding Inhibitor
Druggability: MODERATE-POOR
- Target Class: Heat shock protein co-chaperone (difficult to drug directly)
- Chemical Matter: Limited. No known direct DNAJB6 activators exist
- Existing Tools:
- HSP70 activators (YM-08, SW02) might indirectly enhance DNAJB6 function
- Gene therapy vectors for DNAJB6 overexpression (preclinical only)
- Direct competitors: None targeting DNAJB6 specifically
- Adjacent space: Multiple HSP70/HSP90 programs (Orphazy
⚖ Synthesizer Integrates perspectives and produces final ranked assessments ▼
Price History
7d Trend
↔
Stable
7d Momentum
▼ 1.0%
Volatility
Low
0.0130
Events (7d)
6
⚡ Price Movement Log
Recent 15 events
| Event | Price | Change | Source | Time | |
|---|---|---|---|---|---|
| 📄 | New Evidence | $0.423 | ▲ 3.3% | evidence_batch_update | 2026-04-13 02:18 |
| 📄 | New Evidence | $0.409 | ▲ 6.5% | evidence_batch_update | 2026-04-13 02:18 |
| ⚖ | Recalibrated | $0.384 | ▼ 1.5% | 2026-04-10 15:58 | |
| ⚖ | Recalibrated | $0.390 | ▲ 1.7% | 2026-04-10 15:53 | |
| ⚖ | Recalibrated | $0.383 | ▲ 0.3% | 2026-04-08 18:39 | |
| ⚖ | Recalibrated | $0.382 | ▼ 0.9% | 2026-04-04 16:38 | |
| ⚖ | Recalibrated | $0.385 | ▼ 3.9% | 2026-04-04 16:02 | |
| 📄 | New Evidence | $0.401 | ▲ 4.5% | evidence_batch_update | 2026-04-04 09:08 |
| ⚖ | Recalibrated | $0.384 | ▼ 27.5% | 2026-04-03 23:46 | |
| 📊 | Score Update | $0.530 | ▲ 4.2% | market_dynamics | 2026-04-03 08:36 |
| 📄 | New Evidence | $0.508 | ▲ 40.9% | market_dynamics | 2026-04-03 07:50 |
| 💬 | Debate Round | $0.361 | ▼ 36.4% | market_dynamics | 2026-04-03 07:45 |
| 📄 | New Evidence | $0.567 | ▲ 35.3% | market_dynamics | 2026-04-03 06:48 |
| 💬 | Debate Round | $0.419 | ▼ 2.2% | market_dynamics | 2026-04-03 06:15 |
| 📄 | New Evidence | $0.428 | ▼ 9.4% | market_dynamics | 2026-04-03 04:10 |
Clinical Trials (4) Relevance: 13%
2
Active
Active
1
Completed
Completed
0
Total Enrolled
Total Enrolled
Phase III
Highest Phase
Highest Phase
Elamipretide (SS-31) for Heart Failure
Phase III
Completed
·
NCT02245620
Recruiting
·
NCT04998357
Mitochondrial Protein Import Biomarkers in AD
Observational
Recruiting
·
NCT05269381
Planning
·
NCT04070378
📚 Cited Papers (47)
Transmission dynamics of a linear vanA-plasmid during a nosocomial multiclonal outbreak of vancomycin-resistant enterococci in a non-endemic area, Japan.
Scientific reports (2021) · PMID:34285270
8 figures
Figure 1
Minimum inhibitory concentration of vancomycin and teicoplanin for vancomycin-resistant Enterococcus faecium isolates during the outbreak. According to the criteria of the Clinic...
pmc_api
Figure 2
Dendrogram of pulsotypes in pulsed-field gel electrophoresis and sequence types in multilocus sequence typing among vancomycin-resistant Enterococcus faecium isolates (n = 153). ...
pmc_api
High resolution spatiotemporal patterns of seawater temperatures across the Belize Mesoamerican Barrier Reef.
Scientific data (2020) · PMID:33199700
3 figures
Fig. 1
Map of logger deployment sites in Belize.
pmc_api
Fig. 2
Cross-sectional view of Carrie Bow Caye describing back reef and the two fore reefs in this area: inner fore reef and outer fore reef.
pmc_api
Organelle-specific autophagy in inflammatory diseases: a potential therapeutic target underlying the quality control of multiple organelles.
Autophagy (2021) · PMID:32048886
2 figures
Figure 1.
Quality control of multiple organelles by organelle-specific autophagy. (A) Mitophagy is of great importance in maintaining functional homeostasis of mitochondria, which is initiat...
pmc_api
Figure 2.
Quality control of multiple organelles through organelle-specific autophagy in infection and sepsis. (A) Nucleophagy is critically involved in preventing the invasion of pathogens ...
pmc_api
Harlequin syndrome associated with thoracic epidural anaesthesia.
Anaesthesia reports (2022) · PMID:35118419
1 figure
Figures
Figures available at source paper (no open-access XML found).
deep_link
Loss of prohibitin membrane scaffolds impairs mitochondrial architecture and leads to tau hyperphosphorylation and neurodegeneration.
PLoS genetics (2012) · PMID:23144624
No extracted figures yet
Remediation of textile effluents by membrane based treatment techniques: a state of the art review.
Journal of environmental management (2015) · PMID:25261752
No extracted figures yet
Glycoproteomics Reveals Decorin Peptides With Anti-Myostatin Activity in Human Atrial Fibrillation.
Circulation (2016) · PMID:27559042
No extracted figures yet
Podosome assembly is controlled by the GTPase ARF1 and its nucleotide exchange factor ARNO.
The Journal of cell biology (2017) · PMID:28007915
No extracted figures yet
Prohibitin 2 Is an Inner Mitochondrial Membrane Mitophagy Receptor.
Cell (2017) · PMID:28017329
No extracted figures yet
Macrophage migration inhibitory factor downregulation: a novel mechanism of resistance to anti-angiogenic therapy.
Oncogene (2017) · PMID:28218903
No extracted figures yet
CRISPR-Mediated Base Editing Enables Efficient Disruption of Eukaryotic Genes through Induction of STOP Codons.
Molecular cell (2017) · PMID:28890334
No extracted figures yet
What is cumulative cultural evolution?
Proceedings. Biological sciences (2019) · PMID:29899071
No extracted figures yet
📓 Linked Notebooks (4)
📓 SciDEX Analysis: 2026 04 01 Gap 9137255B
Computational notebook for SDA-2026-04-01-gap-9137255b
📓 Protein aggregation cross-seeding across neurodegenerative diseases — Analysis Notebook
Jupyter notebook for analysis SDA-2026-04-01-gap-9137255b: What are the mechanisms underlying protein aggregation cross-seeding across neurodegenerative diseases?
📓 Protein aggregation cross-seeding across neurodegenerative diseases — Rich Analysis
Enhanced notebook with gene expression, pathway enrichment, score heatmaps, and statistical analysis. What are the mechanisms underlying protein aggregation cross-seeding across neurodegenerative dise …
📓 Protein aggregation cross-seeding across neurodegenerative diseases
What are the mechanisms underlying protein aggregation cross-seeding across neurodegenerative diseases?
Wiki Pages
Cross-Disease Therapeutic Targets in 4R-TauopathietherapeuticMitochondrial Biogenesis InducerstherapeuticMitochondrial Dynamics Modulators for NeurodegenertherapeuticEEDgeneMitochondrial TherapeuticstherapeuticMitochondrial Support Strategies for CBS/PSPtherapeuticEPHB2 GenegeneSleep Disruption and Alzheimer's Disease — mechaniexperimentEPHB2 GenegeneMTCL1 — Microtubule Cross-Linking Factor 1geneSkin Biopsy Tau Seeding in CBS/PSPbiomarkerPlasma α-Synuclein Aggregation Seeding Activity asclinicalNeurodegenerationdiseaseSkin Biopsy Tau Seeding in CBS/PSPbiomarkerERCC2 Gene - Excision Repair Cross-Complementationgene
Related Hypotheses
TREM2-Dependent Astrocyte-Microglia Cross-talk in Neurodegeneration
Score: 0.990 | neurodegeneration
TREM2-Dependent Microglial Senescence Transition
Score: 0.950 | neurodegeneration
PLCG2 Allosteric Modulation as a Precision Therapeutic for TREM2-Dependent Microglial Dysfunction
Score: 0.941 | neurodegeneration
Multi-Biomarker Composite Index Surpassing Amyloid PET for Treatment Response Prediction
Score: 0.933 | neurodegeneration
CYP46A1 Gene Therapy for Age-Related TREM2-Mediated Microglial Senescence Reversal
Score: 0.921 | neurodegeneration
Estimated Development
Estimated Cost
$850,000
Timeline
2.0 years
🧪 Falsifiable Predictions (3)
3 total
0 confirmed
0 falsified
If hypothesis is true, intervention disrupt this hub while preserving PHB2's essential roles in mitochondrial cristae organization and PINK1-Parkin mitophagy signaling
pending
conf: 0.45
Expected outcome: disrupt this hub while preserving PHB2's essential roles in mitochondrial cristae organization and PINK1-Parkin mitophagy signaling
Falsified by: Intervention fails to disrupt this hub while preserving PHB2's essential roles in mitochondrial cristae organization and PINK1-Parkin mitophagy signaling
If hypothesis is true, intervention block tau/α-synuclein/TDP-43 binding
pending
conf: 0.45
Expected outcome: block tau/α-synuclein/TDP-43 binding
Falsified by: Intervention fails to block tau/α-synuclein/TDP-43 binding
If hypothesis is true, intervention be cleared accumulate, producing excess ROS and driving further aggregation
pending
conf: 0.45
Expected outcome: be cleared accumulate, producing excess ROS and driving further aggregation
Falsified by: Intervention fails to be cleared accumulate, producing excess ROS and driving further aggregation
Knowledge Subgraph (0 edges)
No knowledge graph edges recorded
3D Protein Structure
🧬 PHB2 — PDB 3FBT Click to expand 3D viewer
Source Analysis
Protein aggregation cross-seeding across neurodegenerative diseases
neurodegeneration | 2026-04-01 | completed
Community Feedback
0
0 upvotes · 0 downvotes
💬 0 comments
⚠ 0 flags
✏ 0 edit suggestions
No comments yet. Be the first to comment!